Exhibit 99.1 Texas Roadhouse, Inc. Announces Third Quarter 2025 Results Declares Quarterly Dividend of $0.68 per Share LOUISVILLE, KY. (November 6, 2025) – Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 39 weeks ended September 30, 2025. Financial Results Financial results for the 13 and 39 weeks ended September 30, 2025 and September 24, 2024 were as follows: | | 13 Weeks Ended | | | 39 Weeks Ended | | | | --- | --- | --- | --- | --- | --- | --- | | ($000's, except ...

Revenue Performance - Total revenue for the three months ended September 30, 2025, was $241.0 million, a 32.2% increase from $182.3 million in the same period of 2024[148] - For the nine months ended September 30, 2025, total revenue was $395.3 million, reflecting a 23.3% increase from $320.7 million in the same period of 2024[148] - Ticket revenue reached $172,543,000 for the nine months ended September 30, 2025, up 26.1% from $134,243,000 in 2024[152] Attractions and Hospitality Performance - Attractions revenue increased by $31.7 million (32.6%) in Q3 2025, driven by a 21.9% increase in visitors and an 8.7% rise in revenue per visitor[148] - Hospitality revenue rose by $26.7 million (33.7%) in Q3 2025, primarily due to a 35.0% increase in Revenue per Available Room (RevPAR) and a 5.2% increase in available room nights[149] - The number of visitors to attractions reached 1,980,681 in Q3 2025, a 21.9% increase compared to 1,195,856 in Q3 2024[150] - RevPAR for hospitality properties was $280.56 in Q3 2025, a 35.0% increase from $207.85 in Q3 2024[150] - The effective ticket price for attractions was $50.69 in Q3 2025, reflecting a 9.3% increase from $46.37 in Q3 2024[150] - Total visitors increased to 3,575,285 for the nine months ended September 30, 2025, a 14.2% increase compared to 2,588,952 in the same period of 2024[152] Expenses and Operating Costs - Operating expenses increased by 26.3% to $86,592,000 for the three months ended September 30, 2025, primarily due to higher variable costs[154] - Selling, general, and administrative expenses rose by 20.0% to $17,445,000 for the three months ended September 30, 2025, driven by transaction-related costs[156] Cash Flow and Liquidity - Net cash provided by operating activities attributable to continuing operations increased by $40.2 million to $99.783 million for the nine months ended September 30, 2025, compared to $59.566 million in the prior year[168] - Net cash used in investing activities attributable to continuing operations increased by $107.9 million to $145.077 million for the nine months ended September 30, 2025, primarily due to cash paid for the acquisition of Tabacón[169] - Net cash provided by financing activities attributable to continuing operations increased by $108.4 million to $33.953 million for the nine months ended September 30, 2025, compared to a net cash used of $74.469 million in the prior year[170] - As of September 30, 2025, total available liquidity was $274,409,000, significantly up from $49,702,000 at the end of 2024[161] Foreign Currency and Liabilities - The company recorded cumulative unrealized foreign currency translation losses of $51.5 million as of September 30, 2025, down from $62.9 million as of December 31, 2024[174] - The company had long-term contractual liabilities denominated in nonfunctional currencies amounting to $46.4 million as of September 30, 2025[176] - The company experienced an unrealized foreign currency translation gain of $15.5 million during the nine months ended September 30, 2025, compared to a loss of $7.7 million in the prior year[174] Capital Expenditures and Investments - The company has planned capital expenditures of approximately $71 million to $76 million for 2025, including $38 million to $43 million on growth projects[166] - Capital expenditures increased to $44.097 million for the nine months ended September 30, 2025, compared to $40.659 million in the prior year[169] Corporate Developments - The company completed the sale of the GES Business for an aggregate purchase price of $535 million on December 31, 2024[143] - The acquisition of Tabacón Thermal Resort & Spa on July 1, 2025, is expected to generate more evenly distributed revenue throughout the year[146] - The company began trading under the new NYSE ticker symbol PRSU on January 2, 2025, following the transformation into Pursuit Attractions and Hospitality, Inc.[144] Tax and Gains - The effective tax rate decreased to 16.8% for the three months ended September 30, 2025, compared to 17.2% in the same period of 2024[159] - The company recorded a gain of $4.2 million related to business interruption proceeds from the Jasper wildfires during the three months ended September 30, 2025[157]

Exhibit 99.1 Carlsmed®Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., November 6, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30 ...

Clinical Trials and Product Development - 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy across two trials, including 100% remission in Cohort 3 of the RAINIER trial[3] - Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules[4] - Aptevo's pipeline now includes six preclinical candidates targeting various solid tumors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms[18] Financial Performance - The company raised $18.7 million in Q3 2025 and an additional $4.1 million post-quarter, extending its cash runway into Q4 2026[10] - Cash and cash equivalents totaled $21.1 million as of September 30, 2025, increasing to $25.2 million after additional fundraising[10] - Research and development expenses rose to $4.0 million in Q3 2025, up from $3.1 million in Q3 2024, primarily due to increased mipletamig and employee costs[11] - General and administrative expenses increased to $3.6 million in Q3 2025, compared to $2.1 million in Q3 2024, mainly due to higher employee costs[12] - Aptevo reported a net loss of $7.5 million or $2.23 per share for Q3 2025, compared to a net loss of $5.1 million or $357.86 per share in Q3 2024[12] - The total assets of Aptevo increased to $26.996 million as of September 30, 2025, from $15.591 million at the end of 2024[15] - The company’s accumulated deficit reached $269.2 million as of September 30, 2025, compared to $247.6 million at the end of 2024[15] Risks and Uncertainties - Aptevo's actual results may differ materially from forward-looking statements due to various risks, including clinical trial uncertainties and regulatory changes[21] - The company faces known and unknown risks that could impact the availability or commercial potential of its product candidates[21] - Macroeconomic conditions such as rising inflation, interest rates, and decreased consumer confidence are potential factors affecting Aptevo's performance[21] - The ongoing geopolitical risks, including the war between Russia and Ukraine, may also influence the company's business environment[21] - Aptevo does not assume any obligation to update forward-looking statements unless required by law[21]

Revenue Performance - Total revenue for Q3 2025 was $634.4 million, a decrease of 0.7% year-over-year; on a constant currency basis, revenue decreased by 1.2%[6] - Total annual recurring revenue (Total ARR) was $2.536 billion, down 1.7% year-over-year; on a constant currency basis, ARR decreased by 1.5%[6] - Paying users totaled 18.07 million, compared to 18.24 million in the same period last year; average revenue per paying user was $139.07[6] Profitability Metrics - GAAP operating margin improved to 27.5%, up from 20.0% year-over-year; Non-GAAP operating margin increased to 41.1% from 36.2%[6] - GAAP net income was $123.8 million, compared to $106.7 million for the same period last year; Non-GAAP net income was $196.7 million, up from $190.4 million[6] - The company reported a GAAP diluted net income per share of $0.47, compared to $0.34 in the same period last year; Non-GAAP diluted net income per share was $0.74, up from $0.60[6] Cash Flow and Liquidity - Net cash provided by operating activities was $302.1 million, an increase from $274.2 million year-over-year; free cash flow was $293.7 million, up from $270.1 million[6] - Cash, cash equivalents, and short-term investments totaled $925.3 million at the end of the quarter[6] - Cash, cash equivalents, and restricted cash at the end of the period were $764.2 million, a decrease from $1,360.5 million at the beginning of the period[16] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $716.4 million, up from $680.3 million in the same period of 2024, reflecting a growth of about 5%[16] - Free cash flow for the three months ended September 30, 2025, was $293.7 million, up from $270.1 million in the same period of 2024, representing a growth of 8.5%[28] - Unlevered free cash flow for the nine months ended September 30, 2025, was $765.0 million, compared to $661.1 million for the same period in 2024, reflecting a growth of 15.7%[28] Expenses and Investments - Research and development expenses for the three months ended September 30, 2025, were $182.3 million, with a research and development margin of 28.7%[18] - Research and development expenses totaled $545.1 million, with a margin of 28.9%[22] - Sales and marketing expenses were $271.3 million, leading to a margin of 14.4%[22] - General and administrative expenses amounted to $170.2 million, with a margin of 9.0%[22] - The company incurred stock-based compensation expenses of $78.6 million for the three months ended September 30, 2025[16] - Capital expenditures for the three months ended September 30, 2025, were $8.4 million, up from $4.1 million in the same period of 2024[28] Balance Sheet and Assets - Total assets decreased from $3,325.2 million as of December 31, 2024, to $2,795.8 million as of September 30, 2025, representing a decline of approximately 16%[14] - Total current liabilities increased significantly from $1,210.8 million to $1,903.2 million, marking an increase of approximately 57%[14] - Total liabilities increased from $4,077.6 million to $4,327.0 million, indicating a rise of approximately 6%[14] Operational Efficiency - Operating margin for the three months ended September 30, 2025, was 27.5%, reflecting a significant increase in operational efficiency[18] - Income from operations for the nine months ended September 30, 2025, was $526.9 million, reflecting an operating margin of 28.0%[22] - The operating margin for the nine months ended September 30, 2025, was 41.4%[22] Strategic Initiatives - The company launched a self-serve version of Dash, providing access to an AI assistant and search engine for its 575,000 paying businesses[3] - The company is focused on sustainable growth and improving retention in its core business[3] - The company disclosed that it has provided non-GAAP financial measures to give investors additional insights into its performance, including revenue growth on a constant currency basis[29] - Management believes that free cash flow is an important indicator of liquidity and provides useful information regarding cash generated from operations[32] - Non-GAAP measures are used by management to evaluate financial performance and are reconciled to GAAP measures to mitigate limitations[33] Workforce and Restructuring - Total cash payments related to workforce reduction amounted to $13.2 million during the nine months ended September 30, 2025[28] - The company has made payments related to lease termination amounting to $36.0 million during the nine months ended September 30, 2025[28]

Financial Performance - Total revenues for the three months ended September 30, 2025, were $10,882,000, an increase of 4.4% compared to $10,418,000 for the same period in 2024[12] - Net income for the three months ended September 30, 2025, was $8,780,000, representing a 153.5% increase from $3,468,000 in the prior year[12] - Net income for the nine months ended September 30, 2025, was $16,855,000, compared to $7,616,000 for the same period in 2024, representing a 121% increase[17] - Net cash provided by operating activities increased to $16,987,000 for the nine months ended September 30, 2025, from $16,160,000 in 2024, reflecting a growth of 5.1%[17] - The company reported a net loss before taxes of $660,000 for Q3 2025, compared to a loss of $892,000 in Q3 2024[68] - The company reported a net income of $8,780,000 for the three months ended September 30, 2025, compared to a net loss of $3,468,000 for the same period in 2024, representing a significant turnaround[112] Assets and Liabilities - Total assets decreased to $289,362,000 as of September 30, 2025, from $332,235,000 as of December 31, 2024, reflecting a decline of approximately 12.9%[10] - Total stockholders' equity as of September 30, 2025, was $254,206,000, down from $288,690,000 at the end of 2024, indicating a decrease of about 11.9%[10] - Total liabilities decreased to $35,156,000 as of September 30, 2025, from $43,545,000 as of December 31, 2024, a reduction of approximately 19.3%[10] - The carrying value of finance receivables, net, was $245,396,000 as of September 30, 2025, remaining unchanged from its fair value[105] Credit Losses and Impairments - The provision for credit losses for the three months ended September 30, 2025, was a benefit of $931,000, compared to a provision of $1,385,000 in the same period of 2024[12] - The provision for credit losses for the nine months ended September 30, 2025, was a benefit of $1.59 million, compared to a provision of $10.78 million for the same period in 2024[49] - The company incurred a loss on impairment of intangible assets amounting to $209,000 for the three months ended September 30, 2025[12] - The company reported a loss on impairment of intangible assets of $209,000 for the nine months ended September 30, 2025, compared to $5,771,000 in 2024[17] Cash Flow and Dividends - The company reported a cash dividend of $4.00 per share, totaling $49,078,000[14] - Cash dividends paid amounted to $49,078,000 in 2025, while there were no dividends paid in 2024[19] - The company had cash and cash equivalents of $10,206,000 at the end of the period, down from $17,178,000 at the end of the previous year[19] Finance Receivables - The company’s investment in finance receivables increased to $28,500,000 in 2025 from $17,736,000 in 2024, representing a 61% increase[19] - Total gross finance receivables as of September 30, 2025, amounted to $253.136 million, with term loans contributing $241.634 million and royalties $11.502 million[61] - Nonaccrual finance receivables totaled $11.50 million as of September 30, 2025, compared to $14.83 million as of December 31, 2024, a decrease of 22.5%[52] - The company collected $2.5 million on nonaccrual finance receivables for the nine months ended September 30, 2025, compared to $2.6 million for the same period in 2024[52] Employee and Operational Changes - The company had 9 full-time employees as of September 30, 2025, following the sale of substantially all assets of the Pharmaceutical Development segment[22] Debt and Financing - The Company entered into a revolving credit facility with an initial maximum principal amount of $45 million, with the option to increase it by up to $80 million[72] - The Company issued $30.0 million of 9.00% Senior Notes due 2027, with total net proceeds of approximately $30.6 million after deducting costs[78] - The outstanding balance of the 2027 Senior Notes as of September 30, 2025, was $32.969 million, net of debt issuance costs[79] - The Company recognized $0.9 million and $2.7 million of interest expense related to the Notes for the three and nine months ended September 30, 2025, respectively[81] Market and Economic Conditions - The company has a finance receivables portfolio primarily based on floating interest rates, which exposes it to interest rate risk[160] - Inflation may impact partner companies, potentially affecting their ability to repay loans, which could adversely affect the company's investment valuations[162] - The company does not currently engage in interest rate hedging activities, which may expose it to risks from interest rate fluctuations[161] Revenue Recognition - The company’s pharmaceutical development segment generated fee revenue from a collaboration agreement with AptarGroup, Inc., contributing to its revenue recognition[26] - The Company recognized total contract revenue of $2,153,000 for the nine months ended September 30, 2025, compared to $1,711,000 for the same period in 2024, indicating a year-over-year increase of approximately 25.8%[108]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was $223.6 million, a 122.4% increase compared to $100.5 million in the same period of 2024[151]. - Service revenue reached $190.0 million for the three months ended September 30, 2025, up 132.1% from $81.9 million in the prior-year period, primarily due to the acquisition of Satcom Direct[152]. - Equipment revenue increased to $33.6 million for the three months ended September 30, 2025, representing an 80.1% rise from $18.7 million in the same period of 2024, also attributed to the Satcom Direct acquisition[153]. Active Connections - The number of ATG aircraft online as of September 30, 2025, was 6,529, compared to 7,016 in the prior year, indicating a decrease in active connections[139]. - Average monthly connectivity service revenue per ATG aircraft online was $3,407 for the three months ended September 30, 2025, slightly down from $3,497 in the same period of 2024[139]. - The company expects service revenue to decline in the near term due to a decrease in ATG services sold, but anticipates future growth as more aircraft come online with Gogo 5G and Gogo Galileo[154]. Operating Income and Expenses - Operating income for the three months ended September 30, 2025, was $28.7 million, compared to $19.1 million in the same period of 2024[149]. - Total operating expenses for the three months ended September 30, 2025, were $194.8 million, up from $81.5 million in the prior-year period[149]. - The company reported a net loss of $1.9 million for the three months ended September 30, 2025, compared to a net income of $10.6 million in the same period of 2024[149]. Cost Analysis - Cost of service revenue increased 380.8% to $91.6 million for the three months ended September 30, 2025, compared to $19.1 million in the prior year[155]. - Cost of equipment revenue rose 104.6% to $31.0 million for the three months ended September 30, 2025, compared to $15.2 million in the prior year[156]. - Engineering, design, and development expenses increased 60.7% to $15.7 million for the three months ended September 30, 2025, compared to $9.8 million in the prior year[158]. - Sales and marketing expenses increased 57.5% to $13.5 million for the three months ended September 30, 2025, compared to $8.6 million in the prior year[160]. - General and administrative expenses increased 11.8% to $27.9 million for the three months ended September 30, 2025, compared to $24.9 million in the prior year[162]. - Depreciation and amortization expense increased 278.9% to $15.2 million for the three months ended September 30, 2025, compared to $4.0 million in the prior year[164]. - Total other expense increased to $29.3 million for the three months ended September 30, 2025, compared to $6.9 million in the prior year[167]. Tax and Cash Flow - The effective income tax rate for the three months ended September 30, 2025, was (242.8)%, compared to 12.5% in the prior year[169]. - Free Cash Flow is defined as net cash provided by operating activities, plus proceeds from the FCC Reimbursement Program, less purchases of property and equipment[179]. - For the nine months ended September 30, 2025, net cash provided by operating activities was $115.987 million, compared to $79.740 million for the same period in 2024, representing a year-over-year increase of approximately 45%[195]. - Free cash flow for the nine months ended September 30, 2025, was $94.126 million, compared to $81.515 million for the same period in 2024, indicating an increase of about 15.5%[1]. Capital Expenditures and Debt - Capital expenditures for the nine months ended September 30, 2025, were $34.732 million, significantly higher than $18.894 million for the same period in 2024, marking an increase of approximately 83.9%[200]. - The company announced a share repurchase program allowing for the repurchase of up to $50 million of common stock, with approximately $12.1 million remaining available as of September 30, 2025[186]. - The company prepaid $100 million of the outstanding principal amount of the 2021 Term Loan Facility on May 3, 2023, satisfying the required amortization payments for the remaining term[189]. - As of September 30, 2025, cash and cash equivalents at the end of the period were $133.572 million, down from $176.678 million at the end of the same period in 2024[183]. Interest Expense and Risk Management - Interest expense for the nine months ended September 30, 2025, was $50.650 million, compared to $26.193 million for the same period in 2024, reflecting an increase of approximately 93.5%[1]. - The company expects its cash and cash equivalents, along with cash flows from operating activities, to be sufficient to meet its cash requirements for at least the next twelve months[184]. - Capital expenditures are expected to increase in the near term due to the LTE network build-out related to the FCC Reimbursement Program, but this increase will be partially offset by reimbursements from the FCC[201]. - The company has minimal interest rate risk, as a 10% decrease in the average interest rate on its portfolio would have resulted in immaterial reductions in interest income for the three- and nine-month periods ended September 30, 2025 and 2024[209]. Investment Policy and Inflation - The primary objective of the company's investment policy is to preserve capital and maintain liquidity while limiting concentration and counterparty risk[205]. - The company has not used derivative financial instruments for speculation or trading purposes, focusing instead on preserving capital for funding operations[205]. - Inflation has not had a material effect on the company's results of operations, although future impacts cannot be ruled out[210].

Financial Performance - Q3 2025 revenue was $45.9 million, representing a 14% sequential growth[4] - Adjusted EBITDA for Q3 2025 was $5.8 million, up 22% sequentially, with GAAP Net Income of $1.4 million[4] - GAAP gross margin for Q3 2025 was 41.6%, marking the third consecutive quarter with gross margin exceeding 40%[4] - Total revenues for Q3 2025 were $45,893 million, a decrease of 15.1% compared to $54,032 million in Q3 2024[21] - Mobile solutions revenue reached $16,037 million, while fixed wireless access solutions generated $17,650 million, showing significant growth from $9,723 million in the previous year[21] - Operating income for Q3 2025 was $2,155 million, compared to $1,016 million in Q3 2024, indicating a positive trend in operational efficiency[21] - Net income attributable to common stockholders for Q3 2025 was $529 million, a decrease from $8,142 million in Q3 2024[21] - GAAP income from continuing operations for Q3 2025 was $1,432 million, a significant increase from $507 million in Q2 2025[27] - Non-GAAP net income for Q3 2025 reached $2,839 million, up from $2,161 million in Q2 2025, reflecting a 31.3% quarter-over-quarter growth[27] - Adjusted EBITDA for Q3 2025 was $5,751 million, compared to $4,726 million in Q2 2025, indicating a 21.7% increase[27] Guidance and Projections - Q4 2025 financial guidance projects revenue in the range of $45.0 million to $48.0 million and Adjusted EBITDA between $4.0 million and $5.0 million[8] Cash and Assets - Cash and cash equivalents decreased to $14,559 million as of September 30, 2025, down from $39,596 million at the end of 2024[23] - Total current assets were $56,985 million, a decline from $72,900 million as of December 31, 2024[23] - The company reported a net cash used in operating activities of $4,763 million for the nine months ended September 30, 2025, compared to $47,710 million in the same period of 2024[25] Expenses and Liabilities - Research and development expenses for Q3 2025 were $4,878 million, slightly down from $5,176 million in Q3 2024[21] - The total liabilities decreased to $93,531 million as of September 30, 2025, from $112,857 million at the end of 2024[23] - Share-based compensation expense increased to $1,850 million in Q3 2025 from $1,654 million in Q2 2025[27] - Interest expense decreased to $885 million in Q3 2025 from $933 million in Q2 2025, showing a reduction of 5.1%[27] - Depreciation and amortization expenses rose to $2,189 million in Q3 2025, compared to $1,792 million in Q2 2025[27] Leadership and Strategic Developments - A new Tier-1 U.S. carrier customer was secured, with FWA shipments expected to begin late in Q4 2025 and mobile shipments in Q1 2026[4] - The FX4200 enterprise FWA solution was launched, expanding into larger enterprises and creating new market paths via MSPs and MSOs[4] - The company appointed Donna Johnson as CMO and Vishal Donthireddy as CTO, enhancing its leadership team[4] Share Performance - GAAP loss per diluted share improved to $0.03 in Q3 2025 from a loss of $0.03 in Q2 2025[27] - Non-GAAP net income per diluted share for Q3 2025 was $0.12, up from $0.08 in Q2 2025, representing a 50% increase[27] - The number of shares used in computing GAAP income per diluted share was 15,522,042 in Q3 2025, an increase from 15,023,832 in Q2 2025[27] Other Financial Impacts - The company reported a gain on debt restructurings of $16,541 million in Q4 2024, which significantly impacted the financial results[27]

Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the ...

-- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next generation PI3Ka pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients ...